갱년기 관리 시장 예측(-2034년) : 지원 유형별, 증상 유형별, 투여 경로별, 제형별, 최종사용자별, 유통 채널별, 지역별 분석

According to Stratistics MRC, the Global Menopause Support Market is accounted for $18.3 billion in 2026 and is expected to reach $32.0 billion by 2034 growing at a CAGR of 7.2% during the forecast period. Menopause support products encompass pharmaceutical treatments, dietary supplements, and therapeutic delivery systems designed to alleviate symptoms associated with perimenopause and menopause, including hot flashes, mood disturbances, and vaginal atrophy. The market addresses the health needs of the growing aging female population through diverse administration routes and dosage formats. Increasing awareness about menopause management and declining stigma around discussing this life stage are driving product innovation and expanding treatment accessibility across global healthcare systems.

Market Dynamics:

Driver:

Growing aging female population worldwide

Demographic trends show a significant increase in women aged 45-60 globally, creating an expanding addressable market for menopause support solutions. Longer life expectancy means women spend approximately one-third of their lives in post-menopausal phases, intensifying focus on quality of life during these years. Healthcare systems increasingly recognize menopause as a medical concern requiring comprehensive management rather than an inevitable decline. This demographic shift, combined with rising disposable incomes among mature consumers, generates sustained demand for both pharmaceutical interventions and natural support products addressing symptom management and long-term health preservation.

Restraint:

Social stigma and underreporting of symptoms

Cultural taboos surrounding menopause continue to limit market expansion by discouraging open discussions between women and healthcare providers. Many women endure symptoms silently, unaware of available treatment options or reluctant to seek medical assistance due to embarrassment. This communication gap results in significant underdiagnosis and undertreatment, particularly in regions where aging and female health topics remain sensitive. Healthcare provider training often inadequately addresses menopause management, further contributing to low treatment rates. Breaking these cultural barriers requires sustained educational efforts targeting both consumers and medical professionals across diverse global markets.

Opportunity:

Personalized medicine and digital health integration

Advances in genetic testing and biomarker analysis enable tailored menopause treatment approaches based on individual symptom profiles and health histories. Digital health platforms offering symptom tracking, telehealth consultations, and personalized supplement recommendations create new engagement channels with consumers seeking customized solutions. Wearable devices monitoring sleep patterns, skin temperature, and heart rate variability provide objective data for treatment optimization. This convergence of personalized medicine and digital tools allows companies to develop direct-to-consumer relationships, gather real-world evidence on product efficacy, and create subscription-based models ensuring ongoing customer engagement beyond initial product purchase.

Threat:

Regulatory scrutiny of bioidentical hormones

Increasing regulatory attention on compounded bioidentical hormone therapies threatens a significant market segment favored by consumers seeking "natural" alternatives. Health authorities express concerns about inconsistent potency, lack of standardized dosing, and insufficient safety data for custom-compounded preparations. Manufacturing facilities face intensified inspection requirements, while marketing claims face greater restrictions regarding efficacy comparisons to FDA-approved therapies. Regulatory actions limiting compounded hormone availability could disrupt supply chains and consumer access, potentially driving patients toward conventional pharmaceutical options but creating market uncertainty that impacts investment in product development across the menopause support category.

Covid-19 Impact:

The COVID-19 pandemic disrupted menopause support market dynamics through reduced healthcare access and shifting health priorities. Lockdowns limited routine gynecological visits, delaying new diagnoses and treatment initiations. Telehealth adoption partially offset these disruptions, with virtual consultations for menopause management increasing significantly. Stress and lifestyle changes during pandemic periods exacerbated menopausal symptoms for many women, increasing underlying demand. Supply chain interruptions affected availability of specific products, particularly those requiring cold chain storage. Post-pandemic recovery shows sustained telehealth utilization for menopause care and heightened consumer interest in self-managed wellness solutions.

The Oral segment is expected to be the largest during the forecast period

The Oral segment is expected to account for the largest market share during the forecast period, driven by patient familiarity, ease of administration, and extensive product availability. Tablets and capsules represent conventional dosage forms for hormone therapies, dietary supplements, and herbal remedies addressing menopausal symptoms. Oral formulations offer precise dosing, stable shelf lives, and established manufacturing processes ensuring consistent quality. Consumer preference for discrete, portable, and simple daily routines favors oral administration over more invasive alternatives. Pharmaceutical companies continue developing novel oral delivery technologies improving bioavailability and reducing gastrointestinal side effects.

The Patches segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Patches segment is predicted to witness the highest growth rate, offering consistent hormone delivery through transdermal absorption while avoiding first-pass liver metabolism. Patches provide steady symptom relief without oral medication fluctuations, appealing to women seeking predictable outcomes. Convenience factors include once-weekly application schedules eliminating daily dosing requirements. Growing clinical evidence supporting transdermal estrogen safety regarding cardiovascular and thromboembolic risks compared to oral alternatives drives physician recommendations. Product innovations include smaller, more discreet patches with improved adhesion and reduced skin irritation, expanding patient acceptance and compliance across diverse demographics.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by high healthcare awareness, strong pharmaceutical infrastructure, and progressive attitudes toward women's health. Extensive direct-to-consumer advertising educates women about treatment options, while robust insurance coverage improves treatment accessibility. Major market players maintain headquarters and manufacturing facilities throughout the region, ensuring consistent product availability. Clinical research infrastructure generates extensive safety and efficacy data supporting physician prescribing confidence. Professional medical societies actively publish menopause management guidelines, standardizing treatment approaches and encouraging appropriate therapeutic interventions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapidly aging populations, increasing healthcare expenditure, and evolving social attitudes. Countries including Japan, China, and South Korea experience significant demographic shifts with growing cohorts of menopausal women. Rising disposable incomes enable access to premium pharmaceutical and wellness products. Traditional medicine systems incorporating herbal approaches to menopause create natural acceptance of support products. Western pharmaceutical companies increasingly target these markets through strategic partnerships with local distributors. Medical education initiatives improve healthcare provider knowledge, while media discussions gradually reduce cultural stigma surrounding menopause.

Key players in the market

Some of the key players in Menopause Support Market include Bayer AG, Pfizer Inc., AbbVie Inc., Theramex, Astellas Pharma Inc., Eli Lilly and Company, Novartis AG, Amgen Inc., Merck & Co., Inc., GSK plc, Nature's Way Products, LLC, Holland & Barrett Retail Limited, Bonafide Health, LLC, Metagenics, Inc., and Blackmores Limited.

Key Developments:

In February 2026, Bayer presented new real-world evidence from the CHAPTER and REALISE studies at the Menopause Society Annual Meeting, highlighting significant undertreatment in natural menopause and the high use of benzodiazepines for sleep disturbances.

In February 2026, Astellas announced that its non-hormonal drug Veozah (fezolinetant) met its primary endpoint in a Japanese Phase III study, paving the way for regulatory submission and market entry in Japan.

In October 2025, Bonafide released its "State of Menopause" report, revealing that 59% of women aged 40-49 had never heard of perimenopause before experiencing symptoms, driving the company's 2026 strategy toward hormone-free education and clinical-grade supplements.

Support Types Covered:

• Hormonal Therapies
• Non-Hormonal Therapies
• Dietary Supplements
• Lifestyle and Wellness Solutions
• Medical Devices and Digital Therapeutics

Symptom Types Covered:

• Vasomotor Symptoms
• Sleep Disorders
• Mood and Cognitive Symptoms
• Vaginal and Urogenital Symptoms
• Bone Health and Osteoporosis
• Metabolic and Cardiovascular Concerns
• Sexual Health and Libido
• Other Symptoms

Route of Administrations Covered:

• Oral
• Topical and Transdermal
• Injectable
• Vaginal Delivery Systems

Dosage Forms Covered:

• Tablets and Capsules
• Softgels
• Powders
• Liquids and Tonics
• Patches
• Creams and Gels
• Rings and Implants

End Users Covered:

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Homecare Settings
• Wellness Centers and Gynecology Clinics

Distribution Channels Covered:

• Hospitals and Clinics
• Retail Pharmacies and Drug Stores
• Online Pharmacies and E-commerce
• Specialty Stores
• Direct-to-Consumer Platforms

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Menopause Support Market, By Support Type

• 5.1 Hormonal Therapies
  • 5.1.1 Estrogen Therapy
  • 5.1.2 Combined Hormone Therapy
  • 5.1.3 Progesterone Therapy
• 5.2 Non-Hormonal Therapies
  • 5.2.1 Prescription Non-Hormonal Drugs
  • 5.2.2 OTC Non-Hormonal Products
• 5.3 Dietary Supplements
  • 5.3.1 Herbal Supplements
  • 5.3.2 Vitamins and Minerals
  • 5.3.3 Phytoestrogens
  • 5.3.4 Omega Fatty Acids
  • 5.3.5 Probiotics
  • 5.3.6 Combination Supplements
• 5.4 Lifestyle and Wellness Solutions
  • 5.4.1 Fitness and Weight Management
  • 5.4.2 Nutrition Programs
  • 5.4.3 Mental Health and Stress Management
  • 5.4.4 Sleep Support Solutions
• 5.5 Medical Devices and Digital Therapeutics
  • 5.5.1 Pelvic Health Devices
  • 5.5.2 Wearable Health Monitoring
  • 5.5.3 Femtech Platforms
  • 5.5.4 Telehealth and Digital Care Platforms

6 Global Menopause Support Market, By Symptom Type

• 6.1 Vasomotor Symptoms
• 6.2 Sleep Disorders
• 6.3 Mood and Cognitive Symptoms
• 6.4 Vaginal and Urogenital Symptoms
• 6.5 Bone Health and Osteoporosis
• 6.6 Metabolic and Cardiovascular Concerns
• 6.7 Sexual Health and Libido
• 6.8 Other Symptoms

7 Global Menopause Support Market, By Route of Administration

• 7.1 Oral
• 7.2 Topical and Transdermal
• 7.3 Injectable
• 7.4 Vaginal Delivery Systems

8 Global Menopause Support Market, By Dosage Form

• 8.1 Tablets and Capsules
• 8.2 Softgels
• 8.3 Powders
• 8.4 Liquids and Tonics
• 8.5 Patches
• 8.6 Creams and Gels
• 8.7 Rings and Implants

9 Global Menopause Support Market, By End User

• 9.1 Hospitals
• 9.2 Specialty Clinics
• 9.3 Diagnostic Centers
• 9.4 Homecare Settings
• 9.5 Wellness Centers and Gynecology Clinics

10 Global Menopause Support Market, By Distribution Channel

• 10.1 Hospitals and Clinics
• 10.2 Retail Pharmacies and Drug Stores
• 10.3 Online Pharmacies and E-commerce
• 10.4 Specialty Stores
• 10.5 Direct-to-Consumer Platforms

11 Global Menopause Support Market, By Geography

• 11.1 North America
  • 11.1.1 United States
  • 11.1.2 Canada
  • 11.1.3 Mexico
• 11.2 Europe
  • 11.2.1 United Kingdom
  • 11.2.2 Germany
  • 11.2.3 France
  • 11.2.4 Italy
  • 11.2.5 Spain
  • 11.2.6 Netherlands
  • 11.2.7 Belgium
  • 11.2.8 Sweden
  • 11.2.9 Switzerland
  • 11.2.10 Poland
  • 11.2.11 Rest of Europe
• 11.3 Asia Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Australia
  • 11.3.6 Indonesia
  • 11.3.7 Thailand
  • 11.3.8 Malaysia
  • 11.3.9 Singapore
  • 11.3.10 Vietnam
  • 11.3.11 Rest of Asia Pacific
• 11.4 South America
  • 11.4.1 Brazil
  • 11.4.2 Argentina
  • 11.4.3 Colombia
  • 11.4.4 Chile
  • 11.4.5 Peru
  • 11.4.6 Rest of South America
• 11.5 Rest of the World (RoW)
  • 11.5.1 Middle East
    • 11.5.1.1 Saudi Arabia
    • 11.5.1.2 United Arab Emirates
    • 11.5.1.3 Qatar
    • 11.5.1.4 Israel
    • 11.5.1.5 Rest of Middle East
  • 11.5.2 Africa
    • 11.5.2.1 South Africa
    • 11.5.2.2 Egypt
    • 11.5.2.3 Morocco
    • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

• 12.1 Industry Value Network and Supply Chain Assessment
• 12.2 White-Space and Opportunity Mapping
• 12.3 Product Evolution and Market Life Cycle Analysis
• 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

• 13.1 Mergers and Acquisitions
• 13.2 Partnerships, Alliances, and Joint Ventures
• 13.3 New Product Launches and Certifications
• 13.4 Capacity Expansion and Investments
• 13.5 Other Strategic Initiatives

14 Company Profiles

• 14.1 Bayer AG
• 14.2 Pfizer Inc.
• 14.3 AbbVie Inc.
• 14.4 Theramex
• 14.5 Astellas Pharma Inc.
• 14.6 Eli Lilly and Company
• 14.7 Novartis AG
• 14.8 Amgen Inc.
• 14.9 Merck & Co., Inc.
• 14.10 GSK plc
• 14.11 Nature's Way Products, LLC
• 14.12 Holland & Barrett Retail Limited
• 14.13 Bonafide Health, LLC
• 14.14 Metagenics, Inc.
• 14.15 Blackmores Limited